Browse > Article

Combined Effect of Heptaplatin and Ionizing Radiation on Human Squamous Carcinoma Cell Lines  

Ryu, Mi-Ryeong (Department of Radiation Oncology, College of Medicine, The Catholic University of Korea)
Paik, Soon-Young (Department of Microbiology, College of Medicine, The Catholic University of Korea)
Chung, Su-Mi (Department of Radiation Oncology, College of Medicine, The Catholic University of Korea)
Heptaplatin, cis-malonato [(4R,5R)-4,5-bis (amino-methyl)-2-isopropyl-1,3-dioxolane] platinum(II) (SKI-2053R, Sunpla) is a new platinum derivative with antitumor activity comparable to cisplatin on various cancer cell lines. Preclinical studies suggest that it is less nephrotoxic than cisplatin. This study was undertaken to examine the combined effect of heptaplatin and ionizing radiation on two established human squamous carcinoma cell lines (NCI-H520, SQ20B). The cytotoxic activity of heptaplatin was concentration-dependent in both cell lines. When low dose heptaplatin was combined with high dose ionizing radiation, there was an additive cytotoxic effect on NCI-H520 cells (P < 0.05), while a moderate dose of heptaplatin and a low dose of ionizing radiation had an additive cytotoxic effect on the growth of SQ20B cells (P < 0.05). FACS analysis and DAPI staining showed that their additive cytotoxic effects were correlated with the induction of apoptosis. Further studies are warranted using heptaplatin and ionizing radiation in squamous cell carcinoma as a substitute for cisplatin.
Apoptosis; Cytotoxic Effect; Heptaplatin; Ionizing Radiation; Squamous Carcinoma Cell Line;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
Times Cited By Web Of Science : 6  (Related Records In Web of Science)
연도 인용수 순위
1 Dewit, L. (1987) Combined treatment of radiation and cisdiamminedichloro-platinum (II): a review of experimental and clinical data. Int. J. Radiat. Oncol. Biol. Phys. 13, 403-426   ScienceOn
2 Furuse, K., Kubota, K., Kawahara, M., Kodama, N., Ogawara, M., et al. (1995) Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 13, 869-875
3 Kelland, L. R. (1993) New platinum antitumor complexes. Crit. Rev. Oncol./Hematol. 15, 191-219   DOI   ScienceOn
4 Kim, D. K., Kim, H. T., Tai, J. H., Cho, Y. B., Kim, T. S., et al. (1995a) Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato-(4R,5R)-4,5-bis (aminomethyl)-1,3-dioxolane-platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother. Pharmacol. 37, 1-6
5 Kohno, N., Kitahara, S., Tamura, E., and Tanabe, T. (2002) Concurrent chemoradio-therapy with low-dose cisplatin plus 5-Fluorouracil for the treatment of patients with unresectable head and neck cancer. Oncology 63, 226-231   DOI   ScienceOn
6 Leichman, L., McDonald, B., Dindogru, F. A., Samson, M., and Vaitkevicius, V. K. (1984) An active drug in the treatment of disseminated gastric cancer. Cancer 53, 18-22   DOI   ScienceOn
7 Reed, E., Dabholkar, M., and Chabner, B. A. (1996) Platinum analogues; in Cancer Chemotherapy and Biotherapy: Principles and Practice, Chabner, B. A. and Longo, D. I. (eds.), pp. 357, Lippincott-Raven, Philadelphia
8 Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., et al. (1994) Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 10, 263-270   DOI   ScienceOn
9 Gonzalez, V. M., Fuertes, M. A., Alonso, C., and Perez, J. M. (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol. Parmacol. 59, 657-663
10 Kim, D. K., Kim, G., Gam, J., Cho, Y. B., Kim, H. T., et al. (1994a) Synthesis and antitumor activity of a series of 2-substituted-4,5-bis(aminomethyl)-1,3-dioxolaneplatinum(II) complexes. J. Med. Chem. 37, 1471-1485   DOI   ScienceOn
11 Kim, N. K., Kim, T. Y., Shin, S. G., Park, Y. L., Lee, J. A., et al. (2001) A phase I study of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-1,3-dioxolane]plaTINUM(II) in patients with advanced malignancies. Cancer 91, 1549-1556   DOI   ScienceOn
12 Lee, Y. S., Kang, K. S., Shin, D. J., Cho, J. J., Kim, H. O., et al. (1992) Subacute toxicity of cis-malonato(4R,5R)-4,5-bis-(aminomethyl)-1,3-dioxolane-platinum(II) (SKI 2053R) in beagle dogs. Korean J. Toxicol. 8, 235-m254
13 Hong, W. S., Kim, H. T., Kim, K. H., and Kim, D. K. (1995) In vitro antitumor activity of a new platinum complex, cismalonato (4R, 5R)-4,5-bis(aminomethyl)-1,3-dioxolane-platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines. Anticancer Res. 15, 51-54
14 Kim, N. K., Im, S. A., Kim. D. W., Lee, M. H., Jung, C. W., et al. (1999) Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer 86, 1109-1115   DOI   ScienceOn
15 Joiner, M. C., Lambin, P., and Marples, B. (1999) Adaptive response and induced resistance. C. R. Acad. Sci. III. 322, 167-175   ScienceOn
16 Kokubo, M., Nagata, Y., Nishimura, Y., Kimura, H., Shoji, K., et al. (2001) Concurrent chemoradiotherapy for oropharyngeal carcinoma. Am. J. Clin. Oncol. 24, 71-m96   DOI   ScienceOn
17 Tannock, I. F. (1994) New perspectives in combined radiotherapy and chemotherapy treatment. Lung Cancer 10, 29-m51   DOI   ScienceOn
18 Fram, R. J. (1992) Cisplatin and platinum analogues: recent advances. Curr. Opin. Oncol. 4, 1073   ScienceOn
19 Potish, R. A., Twiggs, L. B., and Adcock, L. L. (1986) Effect of cisplatinum on tolerance to radiation therapy in advanced cervical cancer. Am. J. Clin. Oncol. 9, 387-m391   ScienceOn
20 Rosenberg, B. (1999) Platinum complexes for the treatment of cancer: why the search goes on; in Cisplatin. In Chemistry and Biochemistry of a Leading Anticancer Drug, Bernhard, L. (ed.), pp. 3-m27, Wiley-VCH, Basel
21 Sause, W. T., Scott, C., and Taylor, S. (1995) Radiation Therapy Oncology Group (RTOG 88-08) Eastern Cooperative Oncology Group (ECOG 4588): preliminary results of a phase III trial in regionally advanced unresectable nonsmall cell lung cancer with minimum three year follow-up (Abstr). Int. J. Rad. Oncol. Biol. Phys. 32, 109
22 Non-small lung cancer collaborative group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 311, 889-890   ScienceOn
23 Berclaz, G., Gerber, E., Beer, K., Aebi, S., Greiner, R., et al. (2002) Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-year survival after radiochemotherapy. Int. J. Oncol. 20, 1313-1318
24 Ahn, J. H., Kang, Y. K., Kim, T. W., Bahng, H., Chang, H. M., et al. (2002) Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother. Pharmacol. 50, 104-110   DOI
25 O'wyer, P. J., Johnson, S. W., and Hamilton, T. C. (1997) Pharmacology of cancer chemotherapy: cisplatin and its analogues; in Cancer: Principles and Practice of Oncology, De Vita, V. T., Hellman, S., and Rosenberg, S. A. (eds.), pp. 418-m432, Lippincott-Raven, Philadelphia
26 Rose, P. G. (2002) Chemoradiotherapy for cervical cancer. Eur. J. Cancer. 38, 270-278   DOI   ScienceOn
27 Durant, J. R. (1980) Cisplatin: a clinical overview; in Cisplatin, Current Status and New Developments, Prestayko, A. W., Crooke, S. T., and Carter, S. K. (eds.), pp. 317-321, Academic Press, New York, NY
28 Coughlin, C. T. and Richmond, R. C. (1989) Biological and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Sem. Oncol. 16, 31-43
29 Eastman, A. (1999) The mechanism of action of cisplatin: from adducts to apoptosis; in Chemistry and Biochemistry of a Leading Anticancer Drug, Bernhard, L. (ed.), pp. 111-134, Wiley-VCH, Basel
30 Muggia, F. M. and Norris, K. J. (1989) Future of cancer chemotherapy with cisplatin. Semin. Oncol. 16, 123
31 Soresi, E., Clerici, M., and Grilli, R. (1988) A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-dichlorodiamine (platinum III) in the treatment of locally advanced non-small cell lung cancer. Semin. Oncol. 15, 20-m25
32 Wong, L. C., Choo, Y. C., Choy, D., Sham, J. S., and Ma, H. K. (1989) Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol. Oncol. 35, 159-163   DOI   ScienceOn
33 Kim, D. K., Ahn, J. S., Ryu, G., Kim, K. H., Park, C. W., et al. (1994b) General pharmacology of cis-malonato(4R,5R)-4,5-bi(aminomet- hyl)-1,3-dioxolane-platinum(II) (SKI 2053R). Arzneim. Forsch. 44, 1080-1088
34 Kim, D. K., Kim, H. T., Cho, Y. B., Tai, J. H., Ahn, J. S., et al. (1995b) Antitumor activity of cis-malonato(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother. Pharmacol. 44, 441-445
35 Kim, S. J., Kim, J. E., and Moon, I. S. (2004) Paraquat induces apoptosis of cultured rat cortical cells. Mol. Cells 17, 102-m107
36 Merlano, M., Vitale, V., Rosso, R., Benasso, M., Corvo, R., et al. (1992) Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327, 1115-m1121   ScienceOn
37 Tannock, I. F. (1989) Combined modality treatment with radiotherapy and chemotherapy. Radioth. Oncol. 16, 83-101   DOI   ScienceOn
38 Merlano, M., Corvo, R., Margarino, G., Benasso, M., Rosso, R., et al. (1991) Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 67, 915-921   DOI   ScienceOn
39 Carter, S. K. (1984) Cisplatin-past, present and future; in Platinum Coordination Complexes in Cancer Chemotherapy, Hacker, M. P., Douple, E. B., and Krakoff, I. H. (eds.), pp. 359-376, Martinus Nijhoff Publishing, Boston
40 Kalendo, G. S. (2001) Different levels of radiation protection in tumor cell populations. Radiats. Biol. Radioecol. 41, 519-527
41 Loeher, P. J. and Einhorn, L. H. (1984) Drugs five years later. Cisplatin. Ann. Intern. Med. 100, 704   ScienceOn
42 Joiner, M. C., Marples, B., Lambin, P., Short, S. C., and Turesson, I. (2001) Low-dose hypersensitivity : current status and possible mechanisms. Int. J. Rad. Oncol. Biol. Phys. 49, 379-389   DOI   ScienceOn
43 Steel, G. G. and Peckham, M. J. (1979) Exploitable mechanism in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5, 85-m91